Logo
En
En
Fr
  • About us
  • Industry Hi-Tech
  • Environment
  • Medical care
  • Education
  • Services
Manufacture of pharmaceuticals
“RUMA GROUPS” is one of the largest pharmaceutical manufacturers. We are focused on the high quality and availability of our products for people and specialize in the production of tablets, ointments and gels, as well as surgical sutures. The company is the only manufacturer of the full cycle of catgut in Russia.
TOP 10
pharmaceutical producers according to the results of 2020 (in natural terms)*
TOP 5
Russian manufacturers of tablets
(in natural terms)*
THE LEADER among of eye ointments manufacturers in Russia
Reliable manufacturer of modern import-substituting drugs
*RNC Pharma
Quality standards
GMP Guideline on Good Manufacturing Practices
Quality

Strict compliance with the registration dossier
Security

Control of the entire product life cycle
Efficiency

Preclinical and clinical trials
Production capability
“RUMA GROUPS” is a modern industrial complex which consists of two plants: chemical-pharmaceutical and suture surgical materials plant.

• Production of pharmaceutical solid with a capacity of 1.5 billion tablets (among which up to 50 percent are coated tablets) in accordance with the requirements of the GMP standard.

• Production of sterile and non-sterile ointments, gels and drops with a capacity of 20 million tubes per year in accordance with GMP standard requirements.
€12,5
million
Total investment in the modernization and development of ointments, gels and drops production
€15
million
Total investment in the modernization and development of pharmaceutical solid production
Production lines comply with Russian quality standards
The construction and equipping of the workshops in accordance with the GMP standard was carried out by Favea
The efficacy of the patient treatment depends on the quality of pharmaceuticals. With allowance for this, we are constantly developing, introducing innovative equipment and improving production technologies.
27,7 Ha
Total area of the enterprise
200 million
More than 200 million tablet packs per year
25 million
More than 25 million of eye and skin ointment packs
26
Pharmaceutical substances
10 million
Over 10 million running meters of suture materials
Surgical suture material
“RUMA GROUPS” is one of the largest manufacturers of surgical suture materials. The enterprise has suture materials of plant and artificial origin, which are absorbable and non-absorbable by their biodestruction ability. The nomenclature includes 15,000 different types of sterile kits of two-needle and needle-free threads of various lengths. Our products are used in all regions of Russia, near and far-abroad countries.
10 million
running meters of surgical suture materials
100
Over 100 standard sizes
15 000
various ty pes of sterile kits
Innovations
In cooperation with leading academic and educational institutions, the research unit of “RUMA GROUPS” develops new, effective and safe pharmaceuticals.

Development of 6 innovative pharmaceuticals:
  1. For the treatment of oncological diseases with multiple drug resistance

  2. Antibacterial drug for the treatment of infections caused by multi-resistant strains of bacteria

  3. Nonsteroidal anti-inflammatory drug with improved safety profile

  4. Antifungal agents of a new class to which the resistance is not developed

  5. Antiseptic agents of new generation

  6. Antiepileptic drug
Pharmaceuticals
Neurology
Dimephosphon
Mebicar
Coffetamin
Ophthalmology
Oftocipro
Tetracyclinum
Hydrocortisonum
Cold-related diseases treatment
Afludol
Rimantadine
Rinilor (disinfectant)
Gastroenterology
Rumney
Motizhekt
Веfunginum
Dermatology
Lamifungin
Dexpanthenolum
Oncology
Glyciphon
Others
Xymedone
Geparidex
Moxy
Logo
© 2023 Company Inc. All rights reserved.
  • About us
  • Industry Hi-Tech
  • Environment
  • Medical care
  • Education
  • Services
DIMEPHOSPHON
Dimethyloxobutylphosphonylmethylate
ATC code: V03AX
Pharmacotherapeutic group: antiacidotic agent
The presence of vasoactive, neuroprotective, antioxidant, antihypoxic, neurotropic effects of Dimephosphone proves its use in neurology and neurosurgery (in complex therapy) for various pathologies:
  • Cerebrovascular disorders
  • Craniocerebral and neurosurgical injuries
  • Planned neurosurgical surgeries
  • Chronic cerebrovascular insufficiency due to atherosclerosis and hypertension
  • Vegetative dystonia
  • Meniere’s Disease
  • Migraine
PHARMACEUTICAL FORM AND PRESENTATION
  • Oral and topical solution of 15% 100 ml
  • Concentrate for preparation of solution for intravenous administration of 1,0g No. 5,10
MEBICAR
Tetramethyltetraazabicyclooctandionum
ATC code: N05BX
Pharmacotherapeutic group: antianxiety agent (tranquilizer)
  • Relieves nervous tension and irritability
  • Increases mental and physical stability under stress
  • Improves memory and mental capacity
  • Agent of choice for psychosomatic diseases
  • Not addictive
  • Does not cause apathy, drowsiness, muscle weakness and does not violate the coordination of movements
PHARMACEUTICAL FORM AND PRESENTATION
  • Tablets 300mg No. 20
  • Tablets 500mg No. 20
COFFETAMIN
Caffeine + ergotamine
ATC code: N02CA52
Pharmacotherapeutic group: antimigraine agent
  • Ergotamine has a direct vasoconstrictor effect
  • Caffeine has a tonic effect on the cerebral vessels, amplifies the vasoconstrictor effect of ergotamine
PHARMACEUTICAL FORMULA CONFORMS TO THE ACCEPTED STANDARDS FOR RAPID RELIEF OF BILIOUS HEADACHE FROM MEDIUM TO SEVERE
PHARMACEUTICAL FORM AND PRESENTATION
        Coated tablets No. 10, 20
GLYCIFON
Diglycidyl methylphosphonate
ATC code: L01
Pharmacotherapeutic group: antitumour agent
  • Selective cytotoxic effect on tumor cells and harmless to surrounding normal tissues
  • No adverse skin resorptive effect
  • Antiseptic effect
  • Good therapeutic and cosmetic effect
Indications field:
– Squamous cell skin cancer stage 1
– Basalioma (including recurrences after surgical or radiation treatment)
– Precancerous dermatitis
– Senile keratosis
EFFICIENCY OF GLYCIFON OINTMENT WAS CONFIRMED IN THE  LEADING CLINICAL BASES OF THE PHARMACOLOGICAL COMMITTEE

OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: N.N.  PETROV RESEARCH INSTITUTE OF ONCOLOGY, M.F. VLADIMIRSKY  MOSCOW REGIONAL RESEARCH AND CLINICAL INSTITUTE, N.N. BLOKHIN RUSSIAN ONCOLOGICAL SCIENTIFIC CENTER, CENTRAL CIENTIFIC RESEARCH INSTITUTE OF DERMATOVENEROLOGY
PHARMACEUTICAL FORM AND PRESENTATION
        Ointment for topical use 30% 10
MOXY
Moxifloxacin
ATC code: J01MA14
Pharmacotherapeutic group: antimicrobial agent - fluoroquinolone
  • Broad-spectrum bactericidal antibacterial drug
  • Bioequivalent to the original drug
  • High bioavailability - about 91%
  • Rapid distribution in organs and tissues
  • Long half-life
  • Convenient dosing regimen – once a day
PHARMACEUTICAL FORM AND PRESENTATION
        Film coated tablets 400 mg
GEPARIDEX
Heparin sodium + Dexpanthenol + Dimethylsulphoxide
ATC code: C05BA53
Pharmacotherapeutic group: direct anticoagulant agent topicallyapplied + other drugs
  • Heparin has an anti-inflammatory effect, prevents thrombosis, improves local blood flow, promotes connective tissue regeneration
  • Dimethylsulphoxide has anti-inflammatory and anti-edema effects, local analgesic effects, and also contributes to a deeper penetration into the tissue of other ingredients of the drug
  • Dexpanthenol has anti-inflammatory, dermato-protective effect, contributes to regeneration of lesional tissues
AID FOR TRAUMAS, INJURIES, STRETCHING
PHARMACEUTICAL FORM AND PRESENTATION
        Gel for topical use 30 g, 50 g, 100 g
MICROIODE 100
MICROIODE 200
Potassium iodide
ATC code: H03CA
Pharmacotherapeutic group: drugs for the treatment of thyroid disorders, Iodine drugs
  • Prevents the development of hypothyroidism associated with iodine insufficiency
  • Normalizes the size of the thyroid gland in newborns, children and young adults
  • Contains a reduced amount of additives
  • Does not contain gelatin, coloring substances, taste improvers that can cause allergies
EFFECTIVE PROPHYLAXIS AND TREATMENT OF IODINE DEFICIENCY DISEASES
PHARMACEUTICAL FORM AND PRESENTATION
        Tablets 100 mcg No. 50 100
        Tablets 200 mcg No. 50 ,100
XYMEDONE
Hydroxiethyldimethyldihydropyrimidine
ATC code: V03A
Pharmacotherapeutic group: accelerator of tissue repair
  • Accelerates tissue regeneration
  • Reduces the healing time of the burn wound
  • Improves transplantability of dermic grafts in autodermoplasty
  • Has an immunostimulatory effect
  • Has anti-inflammatory and antimicrobial effects
PHARMACEUTICAL FORM AND PRESENTATION
        Tablets 250 mg No. 20, 50
OFTOCIPRO
Ciprofloxacin
ATC code: S03AA07
Pharmacotherapeutic group: antimicrobial agent — fluroquinolone
  • High tolerability
  • Pluripotential
  • Longer bactericidal action due to the ointment form
  • Superior bioavailability
  • High sensitivity of microorganisms
  • Approved for use in children from 2 years
MODERN TREATMENT AND PROPHYLAXIS OF BACTERIAL EYE INFECTIONS
PHARMACEUTICAL FORM AND PRESENTATION
        Ophthalmic ointment 0.3% 3 g
AFLUDOL
Umifenovirum
ATC code: J05AX13
Pharmacotherapeutic group: antiviral agent
  • It specifically inhibits hepatitis A and B viruses, a coronavirus associated with severe respiratory syndrome
  • Provides moderate immunomodulatory effect
  • Increases the organism resistance to viral infections
  • Reduces the general organism intoxication and the clinical implications of viral infection, reduces duration of illness
  • Reduces the incidence of complications associated with viral infection, as well as acute exacerbation of a chronic disease
PROPHYLAXIS AND TREATMENT OF FLU AND ARVI
PHARMACEUTICAL FORM AND PRESENTATION
        Film coated tablets, 50 mg, 100 mg No. 10, 20, 40
RUMNEY
Calcium carbonate + magnesium carbonate
ATC code: A02AX
Pharmacotherapeutic group: antiacid
  • Neutralizes excess hydrochloric acid
  • Protects the gastric mucosa
  • Removes pain, fullness and heaviness in the stomach
  • Approved for use during pregnancy and in children over 12 years old
RAPID RELEASE FROM EPIGASTRIC BURNING FOR 3-5 MINUTES
PHARMACEUTICAL FORM AND PRESENTATION
        Chewable tablet No. 10, 20
ВЕFUNGINUM
Shelf fungus extract + cobaltous chloride
ATC code: A13A
Pharmacotherapeutic group: general tonic plant product
  • Regulates metabolic processes
  • Increases general body resistance
  • Has a general tonic effect
  • Normalizes bowel function
  • Eliminates dyspeptic symptoms
PHARMACEUTICAL FORM AND PRESENTATION
        Oral solution 100 ml
RINILOR
Silver proteinate
Silver proteinate-based disinfectant for topical use.
  • Prevents the penetration of microbes by forming a protective film of silver and proteins
  • Promotes cleansing of skin concerns and mucous membranes, relieves from sense of discomfort
PHARMACEUTICAL FORM AND PRESENTATION
        Bottle with purified water and spray nozzle
        + 1 blister container with a tablet for preparation of solution
LAMIFUNGIN
Terbinafine
ATC code: D01AE15
Pharmacotherapeutic group: antifungal agent
Terbinafine has a wide spectrum of action against fungi, including dermatophytes, as well as yeast fungi.
In 2015, an open, randomized, explanatory study of efficacy and safety of LAMIFUNGIN® gel for topical use of 1% in comparison with LAMIZIL® Dermgel, gel for topical use was performed in patients with pityriasis versicolor, which showed that LAMIFUNGIN® is highly competitive with the registered LAMIZIL® Dermgel in terms of efficacy and safety.
PHARMACEUTICAL FORM AND PRESENTATION
        Gel for topical use 1% 15 g